DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Yunis-Varon syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleYunis-Varon syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for yunis-varon syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FIG4 phosphoinositide 5-phosphatase (FIG4) — FIG4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7K1W · 5.1 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Yunis-Varon syndrome is a rare autosomal recessive condition first described in 1980. A 2023 review states it affects both sexes equally and that most infants do not survive beyond one year. The same review reports the condition is caused by FIG4 gene mutations, is associated with consanguineous marriages and lysosomal defects, and can present with cleidocranial dysplasia, ectodermal anomalies, distal aphalangia, pelvic deformity, hip dislocation, bone fractures, urinary tract abnormalities, and central nervous system abnormalities. A 2021 study identified a novel homozygous missense variant (c.968A>G; p.Gln323Arg) in the FIG4 gene in a neonate born to a consanguineous couple, expanding the known molecular spectrum; that report was the first case from the Saudi population.
A 2008 review of 22 published cases delineated the phenotype as including limb defects, ossification defects, generalised hypotrichosis, and frequently a severe neonatal course. That report described a newborn with previously unreported findings of hydrops fetalis, primary pulmonary hypertension, and unusually severe toe abnormalities. A 2001 report described a 15-year-old girl with severe pre- and post-natal growth retardation, poorly muscled build, micrognathia, ulnar ray oligodactyly, absent clavicles, abnormal scapulae, humeroradial fusion, hip dislocation, small iliac wings, slender tubular bones, and normal intelligence; the authors concluded that while she shared some features with Yunis-Varon syndrome, her normal intelligence and ulnar ray oligodactyly did not support that diagnosis.
No drug treatment is mentioned in any of these abstracts. The 2023 review notes that genetic testing can detect mutations and that prenatal diagnosis by ultrasonography is possible in some cases, and recommends genetic counselling for affected families. What remains missing is any clinical trial, any drug-repurposing study, any animal model testing a specific compound, and any patient stratification beyond the genetic diagnosis. Without funding for preclinical work or a trial design, no pharmacological intervention can be evaluated for this syndrome.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2008 · 21 citations
Yunis–Varon syndrome: Further delineation of the phenotype
AbstractYunis-Varon syndrome (YVS) is a rare autosomal recessive condition characterized by limb defects, ossification defects, generalized hypotrichosis and, frequently, a severe neonatal course. The molecular basis is unknown. We report on a newborn infant with previously undescribed findings, including hydrops fetalis, primary pulmonary hypertension and unusually severe abnormalities of toes. We review clinical data on 22 published cases in order to delineate the phenotype of this condition. Clinical recommendations for prenatal and postnatal evaluation of patients and fetuses at risk are discussed.
A novel syndrome with dwarfism, poorly muscled build, absent clavicles, humeroradial fusion, slender bones, oligodactyly and micrognathia
AbstractWe report on a 15-year-old girl with severe pre- and post-natal growth retardation, poorly muscled build, micrognathia, ulnar ray oligodactyly, absent clavicles, abnormal scapulae, humeroradial fusion, hip dislocation, small iliac wings, slender tubular bones and normal intelligence. An extensive search has failed to ascribe this association to a known condition. This child shared some clinical and radiological features with the Yunis-Varon syndrome but the normal intelligence and the ulnar ray oligodactyly of our patient does not support this diagnosis.
Molecular Syndromology · 2021 · 8 citations · open access
<b><i>FIG4</i></b>-Associated Yunis-Varon Syndrome: Identification of a Novel Missense Variant
AbstractYunis-Varon syndrome (YVS; OMIM 216340) is a rare heterogeneous autosomal recessive disorder with easy recognition of characteristic severe neurological and skeletal abnormalities involving skeletal muscles and cartilages. This cleidocranial dysplasia is characterized by bone and tooth disorders; it also affects the cardiovascular system and tissues from ectoderm with very poor outcomes. Rarely, mutations of the <i>FIG4</i> gene, encoding a 50-phosphoinositide phosphatase have been identified as the cause for YVS. We report a neonate born to a consanguineous couple with typical clinical manifestations of YVS. Using whole-exome sequencing, we identified a novel homozygous missense variant (c.968A&#x3e;G; p.Gln323Arg) in the <i>FIG4</i> gene. Thus, our study expands the molecular and genetic spectrum of <i>FIG4</i>-associated mutations. To our knowledge, this is the first reported case of YVS from the Saudi population.
World Journal of Current Medical and Pharmaceutical Research · 2023 · 0 citations · open access
A review on yunis-varon syndrome
AbstractYunis Varon Syndrome was first discovered by Emilio Yunis and Humberto Varon in the year 1980. It affects both genders in equal number. Most of the infants are with Cleidocranial dysplasia, ectodermal anomalities, distal aphalangia. By the characteristic features which including deformity of the pelvis, dislocation of hips , bone fracture, urinary tract abnormalities, central nervous system abnormalities by this they have reported the condition as Yunis Varon Syndrome. This is an autosomal recessive inherited multisystem disorder due to FIG4 gene mutations, consanguineous marriages, Lysosomal defects, which may leads to improper in the functioning of organs in the infants. Metabolic disorders in which abnormal growth due to some toxic substances in the body. Affected people with this syndrome may experience breathing problems, abnormalities in the skeletal system, congenital heart defects. Genetic testing for mutation can be detected through diagnosis. In some conditions they may also be detected before birth of the baby that is prenatally by ultrasonography.Many of the infants did not survive beyond on year. Genetic counselling will be of benefit for affected individuals and their families.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
